E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 8.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10011762 |
E.1.2 | Term | Cystic fibrosis |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The general objective of the study is to estimate the systemic pharmacokinetics of mannitol after single and multiple dosing of IDPM 400 mg to adult and paediatric cystic fibrosis patients. The specific objectives are as follows:
Primary Objectives-
• Determine the pharmacokinetic parameters of mannitol in adult and paediatric CF patients after a single dose of IDPM • Determine the pharmacokinetic parameters of mannitol in adult and paediatric CF patients after twice daily dosing of IDPM for 5 days • Compare PK of mannitol in adult and paediatric CF patients after single and multiple dosing of IDPM.
|
|
E.2.2 | Secondary objectives of the trial |
• Clinical safety of IDPM in adult and paediatric CF patients after single and multiple dosing. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
•Have given written informed consent to participate in this study in accordance with local regulations • Have a confirmed diagnosis of cystic fibrosis (sweat test and/or genotype) • Be aged >6 years (6–11 for paediatrics, 12–17 for adolescents and greater than or equal to 18 years for adults) • Have FEV1 > 30 % and < 90% predicted |
|
E.4 | Principal exclusion criteria |
• Be investigators, site personnel directly affiliated with this study, or their immediate families. Immediate family is defined as a spouse, parent, child or sibling, whether biologically or legally adopted. • Be considered “terminally ill” or listed for lung transplantation • Have had a lung transplant • Be using nebulised hypertonic saline • Have had a significant episode of haemoptysis (> 60 mL) in the three months prior to enrolment • Have had a myocardial infarction in the three months prior to enrolment • Have had a cerebral vascular accident in the three months prior to enrolment • Have had major ocular surgery in the three months prior to enrolment • Have had major abdominal, chest or brain surgery in the three months prior to enrolment • Have a known cerebral, aortic or abdominal aneurysm • Be breast feeding or pregnant, or plan to become pregnant while in the study • Be using an unreliable form of contraception (female patients at risk of pregnancy only) • Be participating in another investigative drug study, parallel to, or within 4 weeks of study entry (except inhaled mannitol) • Not able to maintain a mannitol free diet from Day -2 until Day 8 of the treatment phase. • Have a known allergy to mannitol • Be using beta blockers • Have uncontrolled hypertension – systolic blood pressure > 190 and / or diastolic blood pressure > 100 • Have a condition or be in a situation which in the Investigator’s opinion may put the subject at significant risk, may confound results or may interfere significantly with the patient’s participation in the study • Be MTT positive. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The following PK endpoints will be calculated for the completed subjects: • Day 1 and 2 (pre-dose Day 1 to 24 h post-dose): Cmax, tmax, AUC0-12h, AUC0-infinity, kel, t½, C12h • Day 7 and 8 (pre-dose Day 1 to 24 h post-dose): Cmax, tmax, AUC0-12h, kel, t½, Cpre-dose, C12h
Safety Endpoints:
• serious adverse events, • treatment related adverse events (defined as being possibly, probably or definitely related to treatment in the opinion of the investigator), • treatment related serious adverse events, • adverse events leading to study withdrawal, • treatment related adverse events leading to study withdrawal, and • deaths |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Information not present in EudraCT |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | No |
E.8.5.1 | Number of sites anticipated in the EEA | 2 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 2 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 2 |